论文部分内容阅读
近年抗生素制剂的发展方向,主要是青霉制剂,先锋毒剂和氨基配糖体制剂三方面,而先锋毒剂居首位。最近在日本纷纷出售的第三代先锋毒剂(如Cefataxime、Ceftizoxime、latamoxef、Cefop-erazome等),对革兰阴性杆菌的抗菌力更有加强,对β内酰胺酶的稳定性也较高。对第二代先锋霉剂(如Cefoxitin、Cefmetazole、Cefuroxime、Cefoti-am等)作用不理想的肠道杆菌、构橼酸菌属、沙雷氏菌属等,临床疗效也较好。另外抗菌谱还扩大到对绿脓杆菌以及葡萄糖不发酵革兰阴性杆菌、厌气杆菌等也有效。对流感杆菌也呈现极小的最小发育阻止浓度,
In recent years, the development direction of antibiotic preparations, mainly penicillin agents, pioneer agents and amino glycosides preparations three aspects, and pioneer poison first. Third-generation pioneer agents (Cefataxime, Ceftizoxime, latamoxef, Cefop-erazome, etc.), recently sold in Japan, have shown greater antibacterial activity against gram-negative bacilli and higher stability to beta-lactamase. The second generation of pioneer mold agents (such as Cefoxitin, Cefmetazole, Cefuroxime, Cefoti-am, etc.) is not ideal for the role of intestinal bacteria, Citrobacter, Serratia bacteria, clinical efficacy is also better. Antibacterial spectrum also expanded to Pseudomonas aeruginosa and glucose non-fermented Gram-negative bacilli, anaerobic bacteria also effective. The influenza bacilli also showed a minimal minimum developmental block concentration,